CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr virus viremia after transplantation.
Shijia LiJianrong GeShiyuan ZhouWenjuan ZhuYue HanSuning ChenShengli XueYing WangHuiying QiuXiao-Jin WuDepei WuPublished in: Clinical and translational medicine (2023)
Keyphrases
- stem cell transplantation
- epstein barr virus
- high dose
- diffuse large b cell lymphoma
- liver failure
- respiratory failure
- human health
- cancer therapy
- drug induced
- cell therapy
- stem cells
- risk assessment
- drug delivery
- climate change
- bone marrow
- mesenchymal stem cells
- acute respiratory distress syndrome
- smoking cessation